Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Elliott

Showing results (821-830 of 905) with videos related to

Pageof 91
Sort By:
Breast Cancer Research : BCR|February 10, 2012
Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinomaGinette Serrero, Douglas M Hawkins, Binbin Yue, et al.
BMJ Open|July 14, 2023
Motor and autonomic concomitant health improvements with neuromodulation and exercise (MACHINE) training: a randomised controlled trial in individuals with spinal cord injuryClaire Shackleton, Soshi Samejima, Alison Mm Williams, et al.
Journal of Medicinal Chemistry|April 2, 2005
Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4Scott N VanderWel, Patricia J Harvey, Dennis J McNamara, et al.
The New Phytologist|July 31, 2024
Genome size is positively correlated with extinction risk in herbaceous angiospermsMarybel Soto Gomez, Matilda J M Brown, Samuel Pironon, et al.
Journal of Medicinal Chemistry|February 7, 2001
Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functionsJ B Smaill, G W Rewcastle, J A Loo, et al.
Journal of Medicinal Chemistry|May 30, 1998
Anhydrolide macrolides. 2. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbazate erythromycin A analoguesG Griesgraber, M J Kramer, R L Elliott, et al.
Blood|December 12, 2001
Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral loadS L Silins, M A Sherritt, J M Silleri, et al.
Bioorganic & Medicinal Chemistry Letters|June 5, 2003
Structure-activity relationships in a series of NPY Y5 antagonists: 3-amido-9-ethylcarbazoles, core-modified analogues and amide isosteresMarlys Hammond, Richard L Elliott, Melissa L Gillaspy, et al.
Plos Pathogens|September 7, 2013
Sexuality generates diversity in the aflatoxin gene cluster: evidence on a global scaleGeromy G Moore, Jacalyn L Elliott, Rakhi Singh, et al.
Journal of Medicinal Chemistry|March 26, 1998
Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factorsG W Rewcastle, D K Murray, W L Elliott, et al.
Pageof 91

Showing results (821-830 of 905) with videos related to

Sort By:
Pageof 91
Breast Cancer Research : BCR|February 10, 2012
Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinomaGinette Serrero, Douglas M Hawkins, Binbin Yue, et al.
BMJ Open|July 14, 2023
Motor and autonomic concomitant health improvements with neuromodulation and exercise (MACHINE) training: a randomised controlled trial in individuals with spinal cord injuryClaire Shackleton, Soshi Samejima, Alison Mm Williams, et al.
Journal of Medicinal Chemistry|April 2, 2005
Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4Scott N VanderWel, Patricia J Harvey, Dennis J McNamara, et al.
The New Phytologist|July 31, 2024
Genome size is positively correlated with extinction risk in herbaceous angiospermsMarybel Soto Gomez, Matilda J M Brown, Samuel Pironon, et al.
Journal of Medicinal Chemistry|February 7, 2001
Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functionsJ B Smaill, G W Rewcastle, J A Loo, et al.
Journal of Medicinal Chemistry|May 30, 1998
Anhydrolide macrolides. 2. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbazate erythromycin A analoguesG Griesgraber, M J Kramer, R L Elliott, et al.
Blood|December 12, 2001
Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral loadS L Silins, M A Sherritt, J M Silleri, et al.
Bioorganic & Medicinal Chemistry Letters|June 5, 2003
Structure-activity relationships in a series of NPY Y5 antagonists: 3-amido-9-ethylcarbazoles, core-modified analogues and amide isosteresMarlys Hammond, Richard L Elliott, Melissa L Gillaspy, et al.
Plos Pathogens|September 7, 2013
Sexuality generates diversity in the aflatoxin gene cluster: evidence on a global scaleGeromy G Moore, Jacalyn L Elliott, Rakhi Singh, et al.
Journal of Medicinal Chemistry|March 26, 1998
Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factorsG W Rewcastle, D K Murray, W L Elliott, et al.
Pageof 91